Abstract:PGAP2 gene has been known to be the cause of "hyperphosphatasia, mental retardation syndrome-3" (HPMRS3). To date, 14 pathogenic variants in PGAP2 have been identified as the cause of this syndrome in 24 patients described in single-case reports or small clinical series with pan-ethnic distribution. We aim to present a pediatric PGAP2 -mutated case, intending to further expand the clinical phenotype of the syndrome and to report our experience on a therapeutic approach to drug-resistant epilepsy. We present the clinical, neuroradiological, and genetic characterization of a Caucasian pediatric subject with biallelic pathogenic variants in the PGAP2 gene revealed by next generation sequencing analysis. We identified a subject who presented with global developmental delay and visual impairment. Brain magnetic resonance imaging showed mild hypoplasia of the inferior cerebellar vermis and corpus callosum and mild white matter reduction. Laboratory investigations detected an increase in alkaline phosphatase. At the age of 13 months, he began to present epileptic focal seizures with impaired awareness, which did not respond to various antiseizure medications. Electroencephalogram (EEG) showed progressive background activity disorganization and multifocal epileptic abnormalities. Treatment with high-dose pyridoxine showed partial benefit, but the persistence of seizures and the lack of EEG amelioration prompted us to introduce ketogenic diet treatment. Our case provides a further phenotypical expansion of HPMRS3 to include developmental and epileptic encephalopathy. Due to the limited number of patients reported so far, the full delineation of the clinical spectrum of HPMRS3 and indications for precision medicine would benefit from the description of new cases and their follow-up evaluations. Ethics committee approval is not required because genetic analyses are only for clinical diagnosis. Consent from patients and parents was obtained to publish detailed medical histories of patients. A.S., M.T., C.V., and S.O. were responsible for the conception and design of the paper; A.S., M.T., C.V., and S.O. wrote the original draft of the paper; S.G., M.P., E.R., G.P., and V.D.G. analyzed data. All authors contributed to the writing of the final manuscript. V.D.G. received research fundings and speaker fees from Eisai srl, GW Pharmaceuticals, Neu-raxpharm, Nutricia, Kanso, and Nestlè. V.D.G., S.G., A.P., M.P., E.R., C.V., and S.O. received financial support from the Italian Ministry of Health (RC 2022-2024) for the IRCCS Mondino Foundation in Pavia, Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. * Drs Saracino and Totaro equally contributed to this investigation (co-first authors) Received: 29 September 2023 Accepted: 02 January 2024 Article published online: 16 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Expanding the Spectrum of Autosomal Dominant ATP6V1A-Related Disease: Case Report and Literature Review

Synonymous variants in the ATP6AP2 gene may lead to developmental and epileptic encephalopathy

[Developmental and epileptic encephalopathy produced by the ATP1A2 mutation]

ATP1A2‐related epileptic encephalopathy and movement disorder: Clinical features of three novel patients

A Heterozygous Pathogenic Variant in the ATP6V1A Gene Triggering Epilepsy in a Large Chinese Pedigree.

ATP6V0C variants impair V-ATPase function causing a neurodevelopmental disorder often associated with epilepsy

ATP6V0C gene variants were identified in individuals with epilepsy, with or without developmental delay

The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives

Childhood-related neural genotype–phenotype in ATP1A3 mutations: comprehensive analysis

An Ultra-Rare Mixed Phenotype with Combined AP-4 and ERF Mutations: The First Report in a Pediatric Patient and a Literature Review

Dominantly acting variants in vacuolar ATPase subunits impair lysosomal/autophagolysosome function causing a multisystemic disorder with neurocognitive impairment and multiple congenital anomalies

Consolidating the Role of Mutated ATP2B2 in Neurodevelopmental and Cerebellar Pathologies

A novel missense variant in the ATPase domain of ATP8A2 and review of phenotypic variability of ATP8A2-related disorders caused by missense changes

PPP3CA gene-related developmental and epileptic encephalopathy: Expanding the electro-clinical phenotype

PGAP2-Related Hyperphosphatasia-Mental Retardation Syndrome: Report of a Novel Patient, Toward a Broadening of Phenotypic Spectrum and Therapeutic Perspectives

Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy

Epilepsy due to potential loss of ATP6V1B2 function with mechanistic insight by a Drosophila Vha55 model

Expanding the Molecular and Clinical Phenotype of Patients With De Novo Variants in KIF5C: A Six Patient Case Series

Case report: Diagnosis of a patient with Sifrim-Hitz-Weiss syndrome, development and epileptic encephalopathy-14, and medium chain acyl-CoA dehydrogenase deficiency

Exome sequencing of ATP1A3-negative cases of alternating hemiplegia of childhood reveals SCN2A as a novel causative gene

Expansion of the neurodevelopmental phenotype of individuals with EEF1A2 variants and genotype-phenotype study